Huanling Zhu

He Huang, Xiao-jun Huang, Jianda Hu, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Early T-cell precursor lymphoblastic leukemia accompanied by prominent blastic plasmacytoid dendritic cell proliferation mimicking blastic plasmacytoid dendritic cell neoplasm: an exceptional case report and literature review

Dongsheng Xu, N. Jiang, Huanling Zhu, 2022, Journal of Cancer Research and Clinical Oncology.

Effect of Antiviral Prophylaxis Strategy for Chemotherapy-Associated Hepatitis B Reactivation in Non-Hodgkin’s Lymphoma Patients with Hepatitis B Virus Infection: A Retrospective Cohort Study

Ting Liu, Huanling Zhu, J. Ji, 2014, Indian Journal of Hematology and Blood Transfusion.

Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review.

Lin Wang, Ting Liu, Huanling Zhu, 2014, Clinical lymphoma, myeloma & leukemia.

Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study

J. Radich, J. Cortes, Q. Jiang, 2020, Leukemia.

Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study

Hao Jiang, Jianxiang Wang, A. Sun, 2020, Clinical Cancer Research.

Mental Health in Persons With Chronic Myeloid Leukemia During the SARS-CoV-2 Pandemic: The Need for Increased Access to Health Care Services

Rong Liang, Q. Jiang, Bing-cheng Liu, 2021, Frontiers in Psychiatry.

Frontline flumatinib versus imatinib in patients with chronic myeloid leukemia in chronic phase: Results from the China randomized phase III study.

J. Gu, Hao Jiang, Jianxiang Wang, 2019, Journal of Clinical Oncology.

MiR-659-3p regulates the progression of chronic myeloid leukemia by targeting SPHK1.

Xin-chuan Chen, Huanling Zhu, B. Xiang, 2018, International journal of clinical and experimental pathology.

Microarray-based analysis and clinical validation identify ubiquitin-conjugating enzyme E2E1 (UBE2E1) as a prognostic factor in acute myeloid leukemia

Yu Qin, Yuhuan Zheng, F. Reu, 2016, Journal of Hematology & Oncology.

OCT-1 Protein Expression Detected by Flow Cytometry Provided Valuable Information in CML Patients Treated with Imatinib MesylateÃ,Â FHigher hOCT-1 Expression Predict Better Outcome.

N. Jiang, Huanling Zhu, Ting Liu, 2009 .

Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Dajun Yang, Q. Jiang, Y. Zhai, 2020 .

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Dajun Yang, Q. Jiang, Y. Zhai, 2022, Journal of Hematology & Oncology.

Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.

M. Baccarani, He Huang, Zhi-xiang Shen, 2015, Blood.

Imatinib compared with second‐generation tyrosine kinase‐inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase

Yan Bai, Fei Li, R. Gale, 2023, American journal of hematology.

Quality‐of‐life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia

Yunfan Yang, Suning Chen, Fanjun Cheng, 2023, Cancer medicine.

Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single‐arm, open‐label, phase 2, multicenter study

Jun Yu Li, Zhijian Xiao, Sujun Gao, 2023, American journal of hematology.

Antiproliferative and Apoptosis Triggering Potential of Paclitaxel-Based Targeted-Lipid Nanoparticles with Enhanced Cellular Internalization by Transferrin Receptors—a Study in Leukemia Cells

Jingcao Huang, Huanling Zhu, B. Xiang, 2018, Nanoscale Research Letters.

Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Dajun Yang, Y. Zhai, Yongping Song, 2022, Journal of Hematology & Oncology.

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Dajun Yang, Y. Zhai, Q. Niu, 2023, Blood.

Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to three months of imatinib therapy: final 5-year results from DASCERN.

G. Saglio, O. Sy, Huanling Zhu, 2024, Haematologica.